PDRN vs Polynucleotide
The difference explained — and why marketing blurs it
If you have been reading about PDRN skincare, you have probably also seen the term "polynucleotide" (PN) — and noticed that brands and clinics use the two terms almost interchangeably. They are related but not identical. This page explains the actual difference, why it matters (and where it does not), and how marketing blurs the line.
The actual difference
Both PDRN and polynucleotide (PN) are DNA-derived ingredients, typically extracted from salmonid fish (salmon, trout). The difference is molecular weight:
- PDRN (polydeoxyribonucleotide) — shorter DNA fragments, generally in the range of 50-1,500 kilodaltons (kDa). This is the form used in nearly all topical cosmetics and in some injectables.
- PN (polynucleotide) — longer, higher-molecular-weight chains. In Korean aesthetic medicine, PN is generally the injectable, longer-lasting form.
There is no universally agreed molecular-weight boundary between PDRN and PN. Different research papers and manufacturers use different cutoffs. The distinction is real in principle but fuzzy in practice — which is exactly why marketing can blur it so easily.
Both forms share the same proposed mechanisms: adenosine A2A receptor activation and nucleotide salvage pathway support (see our main guide for details). The difference is in how long the chains are and, consequently, how long they persist in tissue when injected.
Where the difference matters
The PDRN vs. PN distinction matters most for injectable treatments:
- PN injectables (longer chains) tend to last longer in tissue, so they are preferred for skin rejuvenation procedures where durability matters. Products like Rejuran use PN.
- PDRN injectables (shorter fragments) are used in some protocols, particularly for wound healing where the shorter chains may be metabolized more quickly.
For topical cosmetics (serums, creams, masks), the distinction matters much less. Both PDRN and PN face the same skin-barrier problem: DNA fragments are large molecules and the stratum corneum is designed to keep them out. Whether the fragments are "short" or "long" does not change the fundamental penetration limitation.
Why marketing blurs them
Several reasons:
- Both sound scientific. "Polydeoxyribonucleotide" and "polynucleotide" are both impressive-sounding DNA terms. Consumers do not know the difference, and brands know it.
- The boundary is fuzzy. With no standardized molecular-weight cutoff, a brand can call its ingredient either PDRN or PN depending on which sounds more clinical for the target market.
- Clinical credibility transfer. Injectable PN has real clinical evidence. By using "PN" or "polynucleotide" on a topical product's packaging, brands can暗示 a connection to the injectable literature — even though the topical product faces the same barrier problem regardless of what it is called.
- Regulatory looseness. Cosmetics are not FDA pre-approved, so brands can use whichever term they prefer on the packaging without regulatory pushback.
What to check on a product label
If you want to know what is actually in a PDRN or PN product, check the INCI (ingredient list):
- Sodium DNA — this is PDRN. The most common INCI name for the ingredient in cosmetics.
- Hydrolyzed DNA — also PDRN, just a different INCI naming convention.
- DNA / Polynucleotide — some brands list it this way. Without a molecular-weight specification, you cannot tell if it is PDRN or PN from the label alone.
The practical takeaway: for a topical product, do not choose based on whether it says "PDRN" or "polynucleotide." Choose based on the overall formula quality, the position of the DNA ingredient in the INCI list (higher = more of it), and the supporting ingredients. The PDRN vs. PN distinction only meaningfully affects injectable treatments, where it is the clinician's decision, not yours.
For the full breakdown of PDRN's benefits and limitations, see our benefits & side effects page. For product recommendations, see our PDRN serum and PDRN cream round-ups.
Frequently Asked Questions
What is the difference between PDRN and polynucleotide?
PDRN (polydeoxyribonucleotide) refers to shorter DNA fragments; polynucleotide (PN) refers to longer, higher-molecular-weight chains. Both are DNA-derived and both are used in skincare and aesthetic medicine, but PN is typically the injectable form and PDRN the shorter-fragment form used in most cosmetics and some injectables.
Which is better for skincare: PDRN or PN?
For injectable treatments, PN is generally preferred because the longer chains last longer in tissue. For topical cosmetics, PDRN is more common because the shorter fragments are easier to formulate with. Neither is clearly 'better' — they serve different purposes and the evidence base differs.
Why do brands use PDRN and PN interchangeably?
Marketing. Both terms sound scientific and both are DNA-derived, so brands blur them to make products sound more clinical. There is no standardized cutoff between PDRN and PN molecular weights, so the distinction is fuzzy even in the literature. Always check the ingredient list (INCI) for sodium DNA or hydrolyzed DNA.
Does it matter which one is in my serum?
For a topical serum, not much — the skin barrier limits penetration of both short and long DNA fragments similarly. The distinction matters more for injectables, where PN's longer chains provide longer-lasting effects. For cosmetics, focus on the overall formula quality rather than whether the DNA fragments are labelled PDRN or PN.
References & Sources
- Marques C, et al. Biomolecules (2025) — Nomenclature and molecular-weight ranges (typically 50–1,500 kDa); no standardized cutoff between PDRN and PN.
- Kim ST. Pharmaceutics (2025) — Review of PDRN/PN sources, mechanisms and clinical applications.
- Lampridou S, et al. J Cosmet Dermatol (2025) — Systematic review of aesthetic PN injections — uses PN terminology.